Adamantane Pinene Derivatives Targeting Chlamydiales Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intracellular bacterial infections, particularly those caused by Chlamydiales, face challenges due to antibiotic resistance and the need for more specific pathogens-targeting therapies to prevent the spread of resistance.
Innovation Solution
Development of adamantane and pinene derivatives, specifically compounds of formula (I), which inhibit pathogenic bacteria in the Chlamydiales order, including Chlamydia trachomatis, Chlamydophila pneumoniae, and Simkania negevensis, by targeting their replication cycles and infection processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Chlamydiales infections, then infection treatment is achieved, but antibiotic resistance spreads
Solution Approach 1:
The patent changes the chemical parameters of the treatment agents by synthesizing novel adamantane and pinene derivatives with specific molecular structures (formula I) that differ fundamentally from conventional antibiotics. These compounds modify the interaction parameters with chlamydial proteins, achieving effective treatment while avoiding the resistance mechanisms that develop with repeated conventional antibiotic use.
Solution Approach 2:
The patent employs newly synthesized compounds that can be developed as single-use or limited-duration treatments, replacing the need for long-term antibiotic therapy. The novel compounds (formula I) represent disposable treatment solutions that eliminate resistance pressure by not requiring continuous or repeated dosing, thus treating the infection without fostering antibiotic resistance spread.
2Reliability
If broad-spectrum antibiotics are used to treat Chlamydiales infections, then infection treatment is achieved, but other bacteria are affected
Solution Approach 1:
The patent applies local quality by designing compounds (formula I) with specific molecular structures that target chlamydial proteins with high specificity. The adamantane and pinene derivatives interact selectively with chlamydial translation or replication machinery, providing effective treatment while minimizing off-target effects on other bacterial species, thus avoiding the collateral damage of broad-spectrum antibiotics.
Solution Approach 2:
The patent segments the treatment approach by developing specific compounds targeted at particular chlamydial proteins or pathways rather than using broad-spectrum agents. The formula I compounds represent divided, specialized treatment mechanisms that address specific chlamydiae vulnerabilities without affecting other bacterial populations, enabling precise pathogen targeting.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a method for treating a Chlamydiales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: W-L1-NH-L2-Ar (I) Wherein W, L1, L2 and Ar are as defined in claim 1.